Bakuchiol, a phenolic meroterpenoid from the seeds of Psoralea corylifolia L., has shown promise as an antitumor drug, so researchers at Bengbu Medical University synthesized novel derivatives of bakuchiol bearing modifications on the aromatic ring.
Vaxcellbio Co. Ltd. has signed a research agreement with the Korea Drug Development Fund (KDDF) to pursue the discovery of next-generation targeted anticancer lead compounds based on degradation of the molecular motor protein MYO1D (myosin 1D).
Fibrolamellar carcinoma (FLC) is a rare and lethal cancer accounting for 1% of liver cancers affecting young, otherwise healthy patients. The primary driver of the vast majority of human FLCs is a fusion between the heat shock protein 40 (DNAJB1) and the catalytic subunit α of protein kinase A (PRKACA).
Peptidream Inc. has submitted IND applications to the FDA to initiate phase I studies of [225Ac]PD-32766, as a potential radiotherapeutic, and [64Cu]PD-32766, as the radiodiagnostic pair, for patients with clear cell renal cell carcinoma (ccRCC).
Researchers from Johns Hopkins University, National Institutes of Health and University of Iowa have synthesized superstolide derivatives reported to be useful for the treatment of cancer and viral infections.
Triple-negative breast cancer, which accounts for 15-20% of all cases of breast cancer, is particularly difficult to treat. It is driven in part by epidermal growth factor receptor (EGFR), yet EGFR inhibitors that are effective against other cancers somehow fail to be effective against triple-negative breast cancer.
Researchers from Eilean Therapeutics LLC and collaborators presented the discovery and characterization of a new, selective CDK2 inhibitor showing potent in vitro and in vivo activity at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers from Onco3r Therapeutics BV presented a novel series of selective SMARCA2 small-molecule inhibitors with a best-in-class potency and selectivity profile.
Though immune checkpoint inhibitors have improved the outcomes of patients with hepatocellular carcinoma (HCC), the response rates remain limited. At the annual meeting of the American Association for the Study of Liver Diseases, researchers highlighted N-lysine methyltransferase SMYD2 as an oncogenic protein overexpressed in several tumor types.
RSS
